Metabolic and lipoprotein aspects of polycystic ovarian syndrome

Q Medicine

Clinical Lipidology Pub Date : 2015-06-01 DOI:10.2217/clp.15.12

A. Pazderska, J. Gibney

引用次数: 1

Abstract

Abstract Polycystic ovarian syndrome is a common endocrine disorder of women. It is associated with an adverse metabolic risk factor profile including hyperinsulinemia, abnormal glucose metabolism, dyslipidemia and chronic pro-atherogenic low grade inflammation. A large proportion of PCOS women are overweight or obese; these women have a high prevalence of insulin resistance and some studies suggest this also the case in lean women with PCOS. Impaired glucose tolerance and diabetes are more common in women with PCOS than in the general population. Besides conventional atherogenic dyslipidemia, PCOS women have additional abnormalities including elevations in small, dense LDL and dysfunctional HDL-particles. Despite a clear pro-atherogenic risk factor profile, it has not been clearly demonstrated that this translates into increased cardiovascular morbidity and mortality in this population.

查看原文本刊更多论文

多囊卵巢综合征的代谢和脂蛋白方面

摘要多囊卵巢综合征是一种常见的女性内分泌疾病。它与不良代谢危险因素相关，包括高胰岛素血症、糖代谢异常、血脂异常和慢性促动脉粥样硬化低度炎症。很大一部分多囊卵巢综合征女性超重或肥胖;这些女性胰岛素抵抗的患病率很高，一些研究表明，患有多囊卵巢综合征的瘦弱女性也是如此。糖耐量受损和糖尿病在多囊卵巢综合征女性中比在一般人群中更常见。除了常规的动脉粥样硬化性血脂异常外，PCOS女性还存在其他异常，包括小而致密的LDL升高和功能失调的hdl颗粒。尽管有明确的促动脉粥样硬化危险因素，但还没有明确证明这在这一人群中转化为心血管发病率和死亡率的增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.